Lucentis KAV Study

PHASE3CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Age Related Macular Degeneration
Interventions
DRUG

Ranibizumab

intravitreal injection 3 monthly injections thereafter as needed

DRUG

Verteporfin

Verteporfin photodynamic therapy standard fluence

Trial Locations (3)

A1030

Department of OPhthalmology Medical center east, Vienna

Department of Ophthalmology Rudolf foundation Clinic, Vienna

Department of Ophthalmology, Hospital Hietzing, Vienna

All Listed Sponsors
lead

The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery

OTHER

NCT01570608 - Lucentis KAV Study | Biotech Hunter | Biotech Hunter